RNAC

Peers: CABA KYTX FATE NKTX AUTL SANA ALLO ARGX IMVT CRSP

| Held by: VTI IWM JSML VXF IWN VTWO IWC BUSM IWO QQQS

Index	RUT
Market Cap	189.10M
Enterprise Value	105.34M
Income	-153.94M
Sales	1.48M
Book/sh	-4.17
Cash/sh	4.88
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	75
IPO	Jun 22, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	127.77
P/B	-
P/C	1.28
P/FCF	-
EV/EBITDA	-
EV/Sales	71.18
Quick Ratio	7.48
Current Ratio	7.48
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-5.94
EPS next Y	-4.16
EPS next Q	-1.01
EPS this Y	40.17%
EPS next Y	-38.46%
EPS next 5Y	5.77%
EPS past 3/5Y	- 24.48%
Sales past 3/5Y	-70.66% -29.96%
EPS Y/Y TTM	88.72%
Sales Y/Y TTM	-
EPS Q/Q	-23.51%
Sales Q/Q	-100.00%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	152.40% -100.00%

Insider Own	54.73%
Insider Trans	0.00%
Inst Own	28.84%
Inst Trans	21.08%
ROA	-43.52%
ROE	-
ROIC	-
Gross Margin	-76.57%
Oper. Margin	-6679.69%
Profit Margin	-10422.48%
SMA20	-7.40%
SMA50	-22.29%
SMA200	-18.61%
Trades

Shs Outstand	30.04M
Shs Float	13.70M
Short Float	13.54%
Short Ratio	14.00
Short Interest	1.86M
52W High	11.00 -43.18%
52W Low	5.60 11.61%
Volatility	6.82% 5.81%
ATR (14)	0.41
RSI (14)	33.48
Beta	0.73
Rel Volume	0.00
Avg Volume	132.51K
Volume	28

Perf Week	-0.32%
Perf Month	-17.98%
Perf Quarter	-19.77%
Perf Half Y	-7.41%
Perf YTD	-13.31%
Perf Year	-30.56%
Perf 3Y	-81.40%
Perf 5Y	-94.73%
Perf 10Y	-98.75%
Recom	1.00
Target Price	33.67
Prev Close	6.41
Price	6.25
Change %	-2.50%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-09-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$16
Jul-09-25	Initiated	Wedbush	Outperform	$38
Dec-19-24	Initiated	BTIG Research	Buy	$42
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform	$50
May-24-24	Initiated	Mizuho	Buy	$40
Apr-23-24	Reiterated	H.C. Wainwright	Buy	$2 → $54
Apr-23-24	Initiated	Leerink Partners	Outperform	$39
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform	$1
Jun-14-22	Reiterated	Needham	Buy	$6 → $5
Jun-06-22	Initiated	SVB Leerink	Outperform	$7
Jun-15-21	Initiated	BTIG Research	Buy	$10
Jan-26-21	Upgrade	Mizuho	Neutral → Buy	$2.50 → $8
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Oct-01-20	Downgrade	Mizuho	Buy → Neutral	$2.50
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy	$8
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight	$10
Jan-21-20	Initiated	William Blair	Outperform

Show Previous Ratings

Oct-02-26 07:00AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Sep-29-26 07:30AM	Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis (GlobeNewswire)
Sep-08-26 07:00AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Sep-03-26 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-26 07:00AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
07:00AM	Loading…
Aug-06-26 07:00AM	Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jul-02-26 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jun-12-26 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire) +17.99% -9.57%
Jun-10-26 05:12AM	AstraZenecas extensive obesity drug push; $125M for ultrasound-aided genetic medicine (BioPharma Dive) +8.47%
Jun-09-26 05:19PM	FDA Clears Imvivas Dual-Target CAR-T for Autoimmune Diseases (Exec Edge) +16.89%
07:00AM	Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases (GlobeNewswire)
May-26-26 07:00AM	Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 (GlobeNewswire)
May-12-26 07:00AM	Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-04-26 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +11.41%
Apr-30-26 07:00AM	Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
07:05AM	Loading…
Apr-02-26 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Mar-09-26 07:00AM	Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) +31.68%
Feb-23-26 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-03-26 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jan-14-26 12:00PM	Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-09-26 08:04AM	Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook (GlobeNewswire)
Jan-06-26 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Dec-18-25 04:05PM	Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors (GlobeNewswire)
Nov-13-25 04:05PM	Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis (GlobeNewswire)
Nov-06-25 07:00AM	Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
07:00AM	Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company's Board of Directors (GlobeNewswire)
Oct-28-25 08:45AM	Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates (Zacks) -5.99%
Oct-21-25 03:53AM	Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength? (Zacks)
Oct-03-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
07:00AM	Loading…
Aug-28-25 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 07:00AM	Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -6.56%
Aug-05-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -5.21%
Jul-24-25 07:40AM	Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last? (Zacks)
Jun-24-25 02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks) +5.39%
10:42AM	Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
04:41AM	Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength? (Zacks)
Jun-03-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
May-30-25 07:00AM	Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
May-13-25 07:00AM	Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-08-25 07:00AM	Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 05:35PM	Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -15.03%
May-05-25 07:48AM	Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
May-02-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Apr-08-25 07:00AM	Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial (GlobeNewswire) -5.84%
Apr-02-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Apr-01-25 07:00AM	Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.24%
Mar-14-25 12:15PM	Amgen data muddies outlook for Cartesian, says Oppenheimer (TipRanks)
Mar-13-25 07:00AM	Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
Feb-18-25 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-06-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jan-27-25 07:00AM	Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis (GlobeNewswire)
Jan-13-25 07:00AM	Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases (GlobeNewswire) +8.85%
Jan-07-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Dec-20-24 06:50AM	Cartesian Therapeutics initiated with a Buy at BTIG (TipRanks)
Dec-18-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -7.59%
Dec-04-24 06:33AM	Cartesian Therapeutics Reports Promising Phase 2b Trial Results (TipRanks) +9.56%
Dec-03-24 06:00AM	Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial (GlobeNewswire)
Nov-21-24 07:00AM	Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit (GlobeNewswire)
Nov-14-24 10:01AM	Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 (GuruFocus.com)
Nov-08-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Nov-07-24 07:00AM	Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 09:00AM	Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting (GlobeNewswire)
Oct-15-24 07:00AM	Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting (GlobeNewswire) -5.58%
Oct-04-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +7.45%
Sep-09-24 07:00AM	Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis (GlobeNewswire)
Sep-06-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire) -7.55%
Sep-03-24 07:00AM	Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 (GlobeNewswire) -6.02%
Aug-26-24 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.43%
Aug-07-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jul-08-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jul-03-24 02:25PM	Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates (Zacks) +11.73%
Jul-02-24 04:08PM	Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs (Investor's Business Daily) -35.02%
04:05PM	Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik (GlobeNewswire)
06:31AM	Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus (GlobeNewswire)
06:31AM	Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing (GlobeNewswire)
06:30AM	Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
Jun-06-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
May-23-24 12:12PM	Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08 (Zacks)
May-22-24 07:00AM	Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis (GlobeNewswire)
May-13-24 04:30PM	Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire) +15.38%
12:00PM	What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet (Zacks)
May-10-24 03:12PM	Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ... (GuruFocus.com)
May-08-24 02:52PM	RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 04:15PM	Cartesian Therapeutics Announces New Employment Inducement Grants (Business Wire) -9.85%
Apr-25-24 09:55AM	Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade (Zacks)
Apr-22-24 04:30PM	Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting (Business Wire) +12.76%
Apr-08-24 09:35AM	Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC) (Zacks)
Apr-04-24 07:30AM	Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
07:00AM	Cartesian Therapeutics Announces New Employment Inducement Grants (Business Wire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey) -5.36% -7.55%
Mar-28-24 04:05PM	Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split (GlobeNewswire) -13.83%
Mar-14-24 09:35AM	Cartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-07-24 11:51PM	RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -8.04%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MILOS MILJKOVIC	Former Affiliate	Jun 09 '26	Proposed Sale	6.64	35,038	232,726		Jun 09 04:15 PM
MILOS MILJKOVIC	Former Affiliate	Jun 02 '26	Proposed Sale	6.41	3,924	25,153		Jun 02 04:07 PM
CHRISTOPHER M JEWELL	Former Affiliate	Jan 13 '26	Proposed Sale	7.66	9,000	68,940		Jan 13 04:04 PM
CHRISTOPHER M JEWELL	Former Affiliate	Jan 09 '26	Proposed Sale	8.02	1,510	12,105		Jan 09 04:35 PM
Brunn Carsten	President and CEO	Jan 06 '26	Sale	6.82	23,766	162,077	323,530	Jan 08 04:20 PM
Miljkovic Milos	Chief Medical Officer	Jan 06 '26	Sale	6.82	3,573	24,367	58,820	Jan 08 04:19 PM
Davis Blaine	Chief Financial Officer	Jan 06 '26	Sale	6.82	10,591	72,227	121,220	Jan 08 04:19 PM
English Emily	Chief Operations Officer	Dec 30 '25	Option Exercise	3.30	7,500	24,750	70,226	Jan 02 04:03 PM
BARABE TIMOTHY C	Director	Dec 04 '25	Buy	6.86	30,000	205,797	54,366	Dec 08 04:07 PM
English Emily	Chief Operations Officer	Nov 28 '25	Option Exercise	3.30	7,500	24,750	62,726	Dec 02 04:02 PM
CHRISTOPHER M JEWELL	Former Affiliate	Nov 19 '25	Proposed Sale	7.15	26,935	192,585		Nov 19 04:36 PM

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company was founded on December 10, 2007 is headquartered in Frederick, MD.

PresidentDr. Carsten Brunn Ph.D.

Chief Financial OfficerMr. Blaine T. Davis

Chief Operating OfficerDr. Emily English Ph.D.

Chief Accounting OfficerMs. June Seymour

General Counsel & SecretaryMr. Matthew Bartholomae J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Cartesian Therapeutics Inc

Upgrade your Finviz experience